A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer

This publication has 80 references indexed in Scilit:

• Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial
  The Journal of Pediatrics, 1996
• Prevention of chemotherapy‐induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double‐blind, randomized, phase III study)
  Transfusion, 1996
• Epoetin Alfa
  Drugs, 1995
• Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
  The Lancet, 1994
• Erythropoietin for anaemia in cancer patients
  European Journal Of Cancer, 1993
• Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro
  Annals of Hematology, 1991
• Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium
  Clinical Immunology and Immunopathology, 1991
• Expression of the erythropoietin receptor on a human myeloma cell line
  Biochemical and Biophysical Research Communications, 1990
• Increased Preoperative Collection of Autologous Blood with Recombinant Human Erythropoietin Therapy
  New England Journal of Medicine, 1989
• Erythropoietin receptor of a human leukemic cell line with erythroid characteristics
  Biochemical and Biophysical Research Communications, 1988